Small Cell Lung Cancer Pipeline, FDA Approvals, Unmet Needs, Preclinical and Discovery Stage Product, and Companies 2024 (Updated)

DelveInsight's, "Small Cell Lung Cancer Pipeline Insight 2024" report provides comprehensive insights about 100+ companies and 100+ pipeline drugs in Small Cell Lung Cancer pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Key Takeaways from the Small Cell Lung Cancer Pipeline Report

* DelveInsight's Small Cell Lung Cancer pipeline report depicts a robust space with 100+ active players working to develop 100+ pipeline therapies for Small Cell Lung Cancer treatment.
* The leading Small Cell Lung Cancer Companies include Staidson (Beijing) Biopharmaceuticals Co., Ltd, Cartesian Therapeutics, GEn1E Lifesciences, Aqualung Therapeutics Corp., Theratome Bio, Meridigen Biotech Co., Ltd., Dompe Farmaceutici S.p.A., Veru Healthcare, Windtree Therapeutics, MiNK Therapeutics, Avalo Therapeutics, Inc., Cynata Therapeutics Limited, Thiogenesis Therapeutics, Inc., Arch Biopartners, Ibudilast, and others.
* Promising Small Cell Lung Cancer Therapies in the various stages of development include Amivantamab, Lazertinib, Pemetrexed 500 mg, AL8326 tablets, durvalumab, and others.
* May 2024:- UNICANCER- A Phase II Study of Durvalumab (MEDI 4736) Maintenance in Frail Limited Disease Small Cell Lung Cancer Patients After Thoracic Chemoradiotherapy (CRT). This study is an academic-lead, open-label, multicenter, randomized phase II trial for frail limited disease Small Cell Lung Cancer (LD-SCLC) patients.
* May 2024:- Boehringer Ingelheim- DAREON-8: A Phase I, Open-label, Dose Escalation and Expansion Trial of Repeated Intravenous Infusions of BI 764532 Combined With Standard of Care (Platinium, Etoposide, and Anti-PD-L1) in Patients With Extensive-stage Small Cell Lung Carcinoma.
* May 2024:- Washington University School of Medicine- ADI-PEG 20 in Combination With Gemcitabine and Docetaxel After Progression on Frontline Therapy in Non-small Cell and Small Cell Lung Cancers. In this study, patients with small cell or non-small cell lung cancer will receive ADI-PEG 20, gemcitabine, and docetaxel after demonstrated progression on frontline therapy. In phase I of the study, up to 6 dose levels will be tested to find the recommended phase II dose (RP2D), after which patients enrolling to phase II will be treated at that dose level to assess efficacy.

Request a sample and discover the recent advances in Small Cell Lung Cancer @ Small Cell Lung Cancer Pipeline Outlook Report [https://www.delveinsight.com/sample-request/small-cell-lung-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr]

Small Cell Lung Cancer Overview

Small cell lung cancer is fast-growing lung cancer that develops in the tissues of the lungs. It is the least common type of lung cancer and characterized by rapid, uncontrolled growth of certain cells in the lungs. Small cell lung cancer (SCLC), previously known as oat cell carcinoma, is considered distinct from other lung cancers, which are called non-small cell lung cancers (NSCLCs) because of their clinical and biologic characteristics.

Small cell lung carcinoma (SCLC) arises in peribronchial locations and infiltrates the bronchial submucosa. Symptoms of SCLC are chest pain, chronic cough, coughing up blood, difficulty breathing, facial swelling, fatigue, hoarseness, loss of appetite, swollen neck veins, weight loss, and wheezing. The standard treatment for first- and second-line management of small cell lung cancer (SCLC) is chemotherapy. Immunotherapy has also made progress in the treatment of SCLC including nivolumab, pembrolizumab, atezolizumab, and durvalumab.

Small Cell Lung Cancer Emerging Drugs Profile

* AMG 757: Amgen

AMG 757 is a half-life extended (HLE) anti- delta-like ligand 3 (DLL3) x anti-CD3 BiTE (bispecific T cell engager) molecule. It is being investigated in Phase I clinical studies for the treatment of prostate cancer and Small cell lung cancer.

* APG-1252: Ascentage Pharma

APG-1252 is a highly potent, small-molecule based Bcl-2 family protein inhibitor drug. APG-1252 is designed to treat SCLC, NSCLC, lymphoma, and other solid tumors by selectively blocking Bcl-2 and Bcl-xL to restore the apoptosis process. The drug is in Phase I/II clinical studies for the treatment of SCLC.

Learn more about Small Cell Lung Cancer in clinical trials @ Small Cell Lung Cancer Drugs [https://www.delveinsight.com/sample-request/small-cell-lung-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr]

Small Cell Lung Cancer Therapeutics Assessment

There are approx. 100+ key Small Cell Lung Cancer companies which are developing the therapies for Small Cell Lung Cancer. The Small Cell Lung Cancer companies which have their Small Cell Lung Cancer drug candidates in the most advanced stage, i.e. Phase III include, Ipsen.

DelveInsight's Small Cell Lung Cancer pipeline report covers around 100+ products under different phases of clinical development like

* Late stage products (Phase III)
* Mid-stage products (Phase II)
* Early-stage product (Phase I) along with the details of
* Pre-clinical and Discovery stage candidates
* Discontinued & Inactive candidates
* Route of Administration

Discover more about Small Cell Lung Cancer in development @ Small Cell Lung Cancer Clinical Trials [https://www.delveinsight.com/sample-request/small-cell-lung-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr]

Small Cell Lung Cancer Companies

Staidson (Beijing) Biopharmaceuticals Co., Ltd, Cartesian Therapeutics, GEn1E Lifesciences, Aqualung Therapeutics Corp., Theratome Bio, Meridigen Biotech Co., Ltd., Dompe Farmaceutici S.p.A., Veru Healthcare, Windtree Therapeutics, MiNK Therapeutics, Avalo Therapeutics, Inc., Cynata Therapeutics Limited, Thiogenesis Therapeutics, Inc., Arch Biopartners, Ibudilast, and others.

Small Cell Lung Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

* Oral
* Parenteral
* Intravitreal
* Subretinal
* Topical
* Molecule Type

Small Cell Lung Cancer Products have been categorized under various Molecule types such as

* Monoclonal Antibody
* Peptides
* Polymer
* Small molecule
* Gene therapy
* Product Type

To know more about Small Cell Lung Cancer, visit @ Small Cell Lung Cancer Segmentation [https://www.delveinsight.com/sample-request/small-cell-lung-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr]

Scope of the Small Cell Lung Cancer Pipeline Report

* Coverage- Global
* Small Cell Lung Cancer Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
* Small Cell Lung Cancer Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
* Small Cell Lung Cancer Companies- Staidson (Beijing) Biopharmaceuticals Co., Ltd, Cartesian Therapeutics, GEn1E Lifesciences, Aqualung Therapeutics Corp., Theratome Bio, Meridigen Biotech Co., Ltd., Dompe Farmaceutici S.p.A., Veru Healthcare, Windtree Therapeutics, MiNK Therapeutics, Avalo Therapeutics, Inc., Cynata Therapeutics Limited, Thiogenesis Therapeutics, Inc., Arch Biopartners, Ibudilast, and others.
* Small Cell Lung Cancer Therapies- Amivantamab, Lazertinib, Pemetrexed 500 mg, AL8326 tablets, durvalumab, and others.

For further information on the Small Cell Lung Cancer Pipeline Therapeutics, reach out @ Small Cell Lung Cancer Products Development [https://www.delveinsight.com/sample-request/small-cell-lung-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr]

Table of Content

* Introduction
* Executive Summary
* Small Cell Lung Cancer: Overview
* Pipeline Therapeutics
* Therapeutic Assessment
* Small Cell Lung Cancer - DelveInsight's Analytical Perspective
* In-depth Commercial Assessment
* Small Cell Lung Cancer Collaboration Deals
* Late Stage Products (Phase III)
* Pembrolizumab: Merck & Co
* Drug profiles in the detailed report.....
* Mid Stage Products (Phase II)
* Dostarlimab: GlaxoSmithKline
* Drug profiles in the detailed report.....
* Early Stage Products (Phase I)
* AMG 757: Amgen
* Drug profiles in the detailed report.....
* Preclinical/Discovery Stage Products
* S 055746: Vernalis
* Drug profiles in the detailed report.....
* Inactive Products
* Small Cell Lung Cancer Key Companies
* Small Cell Lung Cancer Key Products
* Small Cell Lung Cancer- Unmet Needs
* Small Cell Lung Cancer- Market Drivers and Barriers
* Small Cell Lung Cancer- Future Perspectives and Conclusion
* Small Cell Lung Cancer Analyst Views
* Small Cell Lung Cancer Key Companies
* Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=small-cell-lung-cancer-pipeline-fda-approvals-unmet-needs-preclinical-and-discovery-stage-product-and-companies-2024-updated]
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/



This release was published on openPR.